Hugo Vanderstichele
Ghent University(BE)Acumen Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Alzheimer's disease research and treatments, Dementia and Cognitive Impairment Research, Parkinson's Disease Mechanisms and Treatments, Statistical Methods in Clinical Trials, Computational Drug Discovery Methods
Most-Cited Works
- → Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects(2009)2,070 cited
- → Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein(1998)1,812 cited
- → Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF(1999)732 cited
- → Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease(1999)667 cited
- → Evaluation of CSF-tau and CSF-Aβ42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice(2001)571 cited
- → Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency(1999)521 cited